QSC tirzepatide is a novel dual GIP and GLP-1 receptor agonist peptide with demonstrated effects on weight management and glycemic control. This synthetic peptide contains 39 amino acids with specific modifications to enhance stability and biological activity.
Our QSC tirzepatide is manufactured under strict quality control standards, ensuring high purity (≥99%) and consistent batch-to-batch performance. The product is supplied as lyophilized powder in sterile vials, suitable for research applications.
Key features of our QSC tirzepatide include:
- Precise molecular structure matching reference standards - Comprehensive analytical testing including HPLC and MS - Available in multiple concentrations from 5mg to 60mg - Custom formulations and packaging available
The mechanism of action of QSC tirzepatide involves simultaneous activation of both GIP and GLP-1 receptors, leading to enhanced insulin secretion, suppressed glucagon release, delayed gastric emptying, and reduced appetite. These combined effects make it a valuable compound for metabolic research.
Note: This product is for research use only. Not for human consumption.